Response to Carboplatin and Paclitaxel in the treatment of hereditary breast ovarian cancer syndrome (HBOC): a case report

被引：0
|
作者：
Mehmood, Faisal [1 ]
Touseef, Mumtaz [2 ]
Ashraf, Amna [2 ]
Rai, Izza Ali [3 ]
机构：
[1] Combined Mil Hosp, Dept Radiol, Lahore, Pakistan
[2] Combined Mil Hosp, Dept Med, Lahore, Pakistan
[3] Combined Mil Hosp, Dept Vasc Surg, Lahore, Pakistan
来源：
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION | 2024年 / 74卷 / 12期
关键词：
Hereditary breast ovarian cancer; Breast cancer; Ovarian cancer; HBOC; BRCA; PALB2; Chemotherapy; Carboplatin; Paclitaxel; PREVALENCE; MUTATIONS;
D O I：
10.47391/JPMA.20059
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The co-occurrence of primary breast cancer and primary ovarian cancer is an exceptional hereditary phenomenon and results from inherent mutations in critical genes like a unique case of hereditary breast-ovarian cancer syndrome (HBOC) reported in Combined Military Hospital, Lahore, Pakistan. It was marked by pathogenic variants in RAD51D, PALB2, CHEK1, and TP53 genes. Remarkably, the patient exhibited an outstanding response to the chemotherapy agents, Carboplatin and Paclitaxel. This dynamic treatment not only led to nearly complete remission of high-grade ovarian serous cancer but also triggered regression in grade-2 invasive ductal breast cancer after just a few rounds of chemotherapy. Consequently, what started as palliative care evolved into a curative triumph.
引用
收藏
页码：2184 / 2187
页数：4
相关论文
共 50 条
  • [21] Hereditary Breast and Ovarian Cancer Syndrome
    Modesitt, Susan C.
    Lu, Karen
    Chen, Lee-May
    Powell, C. Bethan
    OBSTETRICS AND GYNECOLOGY, 2017, 130 (03): : E110 - E126
  • [22] Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study
    Krishnamachari, Bhuma
    Rehman, Mahin
    Cohn, Jason E.
    Chan, Vivian
    Modi, Neil
    Leitner, Ofri
    Tangney, Kelly
    O'Connor, April
    Blazey, William
    Koehler, Sharon
    Tegay, David
    JOURNAL OF CANCER EDUCATION, 2018, 33 (06) : 1213 - 1221
  • [23] Hereditary breast and ovarian cancer syndrome
    Tamaki, Yasuhiro
    CANCER SCIENCE, 2018, 109 : 778 - 778
  • [24] Video Education on Hereditary Breast and Ovarian Cancer (HBOC) for Physicians: an Interventional Study
    Bhuma Krishnamachari
    Mahin Rehman
    Jason E. Cohn
    Vivian Chan
    Neil Modi
    Ofri Leitner
    Kelly Tangney
    April O’Connor
    William Blazey
    Sharon Koehler
    David Tegay
    Journal of Cancer Education, 2018, 33 : 1213 - 1221
  • [25] Carboplatin/paclitaxel/sintilimabImmune myocarditis and no response: case report
    Reactions Weekly, 2023, 1946 (1) : 147 - 147
  • [26] Carboplatin/paclitaxel/trastuzumabNo therapeutic response: case report
    Reactions Weekly, 2021, 1872 (1) : 118 - 118
  • [27] Cisplatin/paclitaxel vs carboplatin/paclitaxel: Optimizing of treatment in advanced ovarian cancer
    Mobus, V
    Jackisch, C
    Luck, HJ
    Meier, W
    Bauknecht, T
    Costa, S
    Richter, B
    Nitz, U
    duBois, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 531 - 531
  • [28] Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
    Tan, Xiangbin
    Zou, Shuangyou
    Chen, Hui
    Chen, Dachao
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (09)
  • [29] Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment
    Weigel, Marion T.
    Rath, Katrin
    Alkatout, Ibrahim
    Wenners, Antonia S.
    Schem, Christian
    Maass, Nicolai
    Jonat, Walter
    Mundhenke, Christoph
    ONCOLOGY, 2014, 87 (04) : 232 - 245
  • [30] Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer
    De Placido, S
    Tramontana, S
    Ferrari, E
    De Matteis, A
    Lauria, R
    Perrone, F
    Bianco, AR
    Gallo, C
    Ricchi, P
    De Placido, G
    Pignata, S
    ANTICANCER RESEARCH, 2000, 20 (5C) : 4023 - 4029
12345